logo
logo

Splicebio Raises Eur 50M In Oversubscribed Series A Financing To Advance Protein Splicing Platform And Expand Gene Therapy Pipeline

Splicebio Raises Eur 50M In Oversubscribed Series A Financing To Advance Protein Splicing Platform And Expand Gene Therapy Pipeline

02/16/22, 2:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/ES.svgbarcelona
Money raised
€50 million
Round Type
series a
SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The financing was co-led by UCB Ventures and existing shareholder Ysios Capital and joined by new investors New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners. The Company was seeded in 2020 by Ysios Capital and Asabys Partners.

Company Info

Company
Splice Bio
Location
barcelona, catalonia, spain
Additional Info
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. The Company's proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio's platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. For additional information, please visit www.splice.bio.